References
- Shen C, Chien CR, Geynisman DM, et al. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoeconomics Outcomes Res 2014;14:45-69
- Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-14
- Borner M, Scheithauer W, Twelves C, et al. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 2001;6(Suppl 4):12-16
- Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
- Colomer R, Alba E, Gonzalez-Martin A, et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol 2010;21:195-8
- Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 2012;16:432-8
- Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discovery Med 2013;15:231-41
- Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians 2009;59:56-66
- Situation de la chimiothérapie des cancers. Institut National Du Cancer 2012. Available at: http://www.e-cancer.fr/en/rss-soins/7763-rapport-annuel-sur-la-situation-de-la-chimiotherapie-des-cancers [Last accessed 25 March 2014]
- O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002;87:933-7
- Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep 2010;12:247-52
- Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012: Etude à partir des registres des cancers du réseau Francim – Partie 1: tumeurs solides. Institut National de Veille Sanitaire, 2013. Available at: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2013/Estimation-nationale-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-entre-1980-et-2012 [Last accessed 27 October 2014]
- Estimation nationale de l’incidence des cancers en France entre 1980 et 2012: Étude à partir des registres des cancers du réseau Francim Partie 2 – Hémopathies malignes. Institut National de Veille Sanitaire, 2013. Available at: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2013/Estimation-nationale-de-l-incidence-des-cancers-en-France-entre-1980-et-2012 [Last accessed 27 October 2014]
- Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Canc Res Treat 2005;92:265-72
- Les cancers en France. Institut National Du Cancer, 2013. Available at: http://www.e-cancer.fr/publications/69-epidemiologie/758-les-cancers-en-france-edition-2013 [Last accessed 17 February 2014]
- Benjamin L, Buthion V, Vidal-Trécan G, Briot P. Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts. BMC Health Serv Res. 2014;14:274
- Van Nuys K, Conoshenti J, Goldman D. Practice economics and the decision to prescribe oral oncolytics. Am J Pharm Benefits 2013;5(Special Issue):SP29-31
- Pertinence du développement de la chimiothérapie en Hospitalisation à domicile: analyse économique et organisationnelle. Haute Autorité de Santé, 2013. Available at: http://www.has-sante.fr/portail/jcms/c_1696038/fr/pertinence-du-developpement-de-la-chimiotherapie-en-hospitalisation-a-domicile-analyse-economique-et-organisationnelle [Last accessed 27 October 2014]
- Lee YH, Jeong IS. Factors influencing medication adherence to oral anticancer drugs [Korean]. Asian Oncol Nurs 2013;13:201-9